BIOLIGHT(SZ:300246) Xin Lang Cai Jing·2025-10-13 02:09Core Viewpoint - Baolait's stock price has experienced a decline recently, with a year-to-date increase of 22.91% but a notable drop in the last 60 days of 13.46% [1] Group 1: Stock Performance - On October 13, Baolait's stock fell by 4.59%, trading at 8.10 yuan per share, with a total market capitalization of 2.143 billion yuan [1] - The stock has seen a net outflow of 2.0895 million yuan in principal funds, with large orders accounting for 20.69% of sales [1] - Over the past five trading days, the stock has decreased by 3.91%, and over the last 20 and 60 days, it has dropped by 8.37% and 13.46%, respectively [1] Group 2: Company Overview - Guangdong Baolait Medical Technology Co., Ltd. was established on June 28, 1993, and listed on July 19, 2011 [1] - The company specializes in the research, production, sales, and service of medical device products, with revenue composition: 77.51% from blood dialysis products, 21.39% from monitoring devices, and 1.10% from other products [1] - Baolait is classified under the pharmaceutical and biological industry, specifically in medical devices [1] Group 3: Financial Performance - As of June 30, Baolait reported a decrease in operating revenue to 523 million yuan, down 2.43% year-on-year, while net profit attributable to shareholders increased by 152.22% to 1.3134 million yuan [2] - The company has distributed a total of 244 million yuan in dividends since its A-share listing, with 35.1578 million yuan distributed in the last three years [3] Group 4: Shareholder Information - As of June 30, 2025, Baolait had 18,400 shareholders, a decrease of 6.12% from the previous period, with an average of 11,477 circulating shares per shareholder, an increase of 6.50% [2] - Among the top ten circulating shareholders, Jin Yuan Shun An Yuan Qi Flexible Allocation Mixed Fund increased its holdings by 259,800 shares, while Hua Xia Zhong Zheng 500 Index Enhanced A became a new shareholder with 1,228,900 shares [3]